The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2

Birthe Jessen, Sebastian F. N. Bode, Sandra Ammann, Subarna Chakravorty, Graham Davies, Jana Diestelhorst, Melissa Frei-Jones, William A. Gahl, Bernadette R. Gochoico, Matthias Griese, Gillian Griffiths, Gitta Janka, Christoph Klein, Tamara KögI, Karin Kurnik, Kai Lehmborg, Andrea Maul-Pavicic, Andrew D. Mumford, David Pace, Nima Parvaneh, Nima Rezaei, Geneviève de Saint Basile, Annette Schmitt-Graeff, Klaus Schwarz, Gulsun T. Karasu, Barbara Zieger, Udo zur Stadt, Peter Aichele, and Stephan Ehl

1Centre of Chronic Immunodeficiency, University Medical Center Freiburg and University of Freiburg, Germany; 2Department of Medicine, Imperial College London, United Kingdom; 3Immunology Department, Great Ormond Street Hospital for Children, London, United Kingdom; 4Department of Pediatrics, Dr von Hauner Children’s Hospital, Ludwig Maximilian University, Munich, Germany; 5The University of Texas Health Science Center San Antonio, San Antonio, TX; 6Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD; 7Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Cambridge, United Kingdom; 8University Medical Center Hamburg Eppendorf, Department of Pediatric Hematology and Oncology, Hamburg, Germany; 9Department of Immunology, Institute of Medical Microbiology and Hygiene, University of Freiburg, Germany; 10Bristol Heart Institute, University of Bristol, Bristol, United Kingdom; 11Department of Paediatrics, Mater Dei Hospital, Ta’-Tart, Malta; 12Pediatric Infectious Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran; 13Research Center for Immunodeficiencies, Children’s Medical Center, and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 14INSERM U768, Université Paris Descartes, Hôpital Necker-Enfants Malades, Paris, France; 15Institute of Pathology, University Medical Center Freiburg, Freiburg, Germany; 16Institute for Transfusion Medicine, University of Ulm, Ulm, Germany; 17Division of Hematology and Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey; 18Center for Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Germany; and 19Center for Diagnostic, University Medical Center Hamburg Eppendorf, Hamburg, Germany

Key Points
- Hermansky-Pudlak syndrome type 2 confers a moderate risk for hemophagocytic lymphohistiocytosis.

Genetic disorders of lymphocyte cytotoxicity predispose patients to hemophagocytic lymphohistiocytosis (HLH). Reduced lymphocyte cytotoxicity has been demonstrated in Hermansky-Pudlak syndrome type 2 (HPS2), but only a single patient was reported who developed HLH. Because that patient also carried a potentially contributing heterozygous RAB27A mutation, the risk for HLH in HPS2 remains unclear. We analyzed susceptibility to HLH in the pearl mouse model of HPS2. After infection with lymphocytic choriomeningitis virus, pearl mice developed all key features of HLH, linked to impaired virus control caused by a moderate defect in CTL cytotoxicity in vivo. However, in contrast to perforin-deficient mice, the disease was transient, and all mice fully recovered and controlled the infection. An additional heterozygous Rab27a mutation did not aggravate the cytotoxicity defect or disease parameters. In the largest survey of 22 HPS2 patients covering 234 patient years, we identified only 1 additional patient with HLH and 2 with incomplete transient HLH-like episodes, although cytotoxicity or degranulation was impaired in all 16 patients tested. HPS2 confers a risk for HLH that is lower than in Griscelli or Chediak-Higashi syndrome, probably because of a milder defect in cytotoxicity. Preemptive hematopoietic stem cell transplantation does not appear justified in HPS2. (Blood. 2013;121(15):2943-2951)

Introduction

Hermansky-Pudlak syndrome type 2 (HPS2) is a rare autosomal-recessive disorder of lysosomal trafficking caused by mutations in the gene encoding the β3A subunit of the adaptor protein 3 complex (AP-3).1,2 Patients with HPS2 display occlusalocutaneous albinism, bleeding diathesis, neutropenia, interstitial lung disease, pulmonary fibrosis, and suffer from recurrent infections.3 Immunological studies have shown that AP-3 deficiency leads to a defect in cytotoxicity of natural killer (NK) cells and cytotoxic T cells (CTL) as the result of impaired biogenesis and degranulation of perforin-containing lytic granules.4,7 Defective cytotoxicity caused by impaired degranulation also is observed in other disorders of lysosomal trafficking, such as Chediak-Higashi syndrome (CHS) and Griscelli syndrome type 2 (GS2), which are associated with albinism and in familial hemophagocytic lymphohistiocytosis (FHL) types 3-5.8,9 All of these diseases confer a high risk of developing hemophagocytic lymphohistiocytosis (HLH), a severe disorder of immune homeostasis that leads to a life-threatening hyperinflammatory disease. Hematopoietic stem cell transplantation (HSCT) can eliminate this risk and is therefore an important consideration at diagnosis.8,10

We have previously described 1 patient with HPS2 who developed severe HLH that was eventually lethal.5 This case, however,
is the only one of severe HLH among 12 published patients with HPS2.2,5,7,11-14 Because this patient also carried a heterozygous RAB27A mutation (causing GS2, if homozygous), it remains unclear whether HPS2 per se confers a risk for HLH or if the HLH observed in that patient was attributable to this additional mutation. Transient episodes of HLH were thereafter described in another patient with HPS2,2 and 1 additional patient had recurrent inflammatory episodes that did not fulfill all diagnostic criteria for HLH.7 Overall, the risk of developing HLH in HPS2 remains incompletely defined. However, this risk is important for clinical decision-making because preventive treatment is available in the form of HSCT.

In this study, we used 2 approaches to address this problem. First, we analyzed pearl mice, who represent a mouse model for AP-3-deficiency, in an experimental system known to provoke HLH in mouse strains with cytotoxicity defects. Although mice deficient in perforin, Rab27a, Lyst, Unc13d, or Syntaxin-11 do not develop HLH spontaneously, they develop all clinical features of the disease after infection with lymphocytic choriomeningitis virus (LCMV).15-20 This approach allowed us to compare the susceptibility to HLH of pearl mice with that of other cytotoxicity mutants after a defined viral trigger and to assess the impact of an additional heterozygous Rab27a mutation on the phenotype. Second, we performed a survey of all 12 published and 10 previously unreported HPS2 patients to document the clinical evolution of their disease and—if available—the extent of their cytotoxicity defect. Our data show that the risk of developing HLH in HPS2 is relatively low because of a milder cytotoxicity defect. Considering the small risks and serious long-term pulmonary complications of the disease, which are not influenced by HSCT,21 pre-emptive HSCT is probably not indicated in HPS2.

**Methods**

**Mice and virus**

C57BL/6 mice were purchased from Charles River Laboratories (Sulzfeld, Germany). Perforin-deficient (PKO) mice were originally generated on a C57BL/6 background by D. Kägi22 and were kindly provided by H. Pircher (IMMH, Freiburg, Germany). B6.Pin.C3-Ap3b1pefl/fl (stock no. 003215; pearl2) mice (backcross to C57BL/6) were purchased from The Jackson Laboratory (Bar Harbor, ME) and C57BL/6J-ashen (ashen) mice backcrossed to C57BL/6 for 10 generations were kindly provided by G. de Saint Basile (INSERM, Paris, France). Pearl mice carrying a heterozygous Rab27a mutation were obtained by mating of pearl and ashen mice (pearl-ash+/−). Mice were kept in an individual ventilated cage unit (BioZone, Kent, UK) and infected at the age of 6-12 weeks. The lymphocytic choriomeningitis virus WE (LCMV-WE) was provided by H. Pircher (IMMH, Freiburg, Germany). LCMV was grown on MC57G fibroblasts and stored at 80°C until use. Mice were injected intravenously with 200 plaque-forming units (pfu) or 105 pfu as indicated. A focus-forming assay was used as described to quantify virus in organs from infected mice.54

**HLH biomarkers in mice**

Ferritin serum levels were measured by use of the Roche Modular Analytics EVO. Levels of scCD25 were analyzed with the mouse IL-2RalphalDuoSet kit (R&D Systems) according to the instructions of the manufacturer. The interferon (IFN)-γ enzyme-linked immunosorbent assay was performed as described previously.17 Blood cell counts were determined with the Sysmex KX-21 hematology analyzer.

**Lymphocyte phenotyping and intracellular cytokine staining**

For flow cytometry, the following antibodies were used: CD3e (145-2C11; ebioscience), CD8a (53-6.7; BD), CD107a (1D4B; ebioscience), NK1.1 (PK136; BD), IFN-γ (XMG1.2; BD), tumor necrosis factor-α (TNF-α; MP6-XT22; BD), KLRG1 (2F1; ebioscience), CD127 (A7R34; ebioscience), CD44 (IM7; ebioscience), and CD62L (MEL-14; ebioscience). To analyze the intracellular IFN-γ or TNF-α production of CTL, spleen cells were restimulated with gp33 peptide (PolyPeptide, France) for 3 hours in the presence of monensin (BD). After surface staining, cells were fixed, permeabilized, and stained intracellularly for the respective cytokines.

**Degranulation and cytotoxicity assays**

To analyze NK-cell degranulation, mice were injected intraperitoneally with 200 μg of polynosinic acid/polycytidylic acid (poly [I:C]; Sigma-Aldrich). One day later, spleen cells were restimulated for 2 hours with the NK-sensitive YAC-1 target cells or medium as a control in the presence of anti-CD107a antibody. Degranulation of NK.1CD3− NK cells was determined by flow cytometry. NK-cell cytotoxicity was determined by a 5-hour incubation of spleen cells with 51chromium-loaded YAC-1 target cells. Quantification of NK cells was performed by flow cytometry to calculate the NK-cell/target ratio. Surface expression of CD107a and intracellular IFN-γ expression of CD8+CD3− CTL were determined by flow cytometry. CTL cytotoxicity was determined in a 5-hour 51chromium-release assay by incubating spleen cells as effectors with either EL-4 or LCMV-infected MC57G cells as targets.25 To calculate the CTL/target ratio, CD8 T cells were quantified by antibody staining.

**Adoptive transfer experiments**

Splenic CD8 T cells from mice that had been infected with LCMV 8 days earlier were magnetic-activated cell sorting (MACS)-purified with use of the MACS CD8α+ T Cell Isolation Kit II (Miltenyi Biotec). Purity was >90% in all experiments. A total of 2 × 106 purified CD8 T cells were transfused into C57BL/6 mice that had been infected with 105 pfu LCMV 10 hours before, and after additional 18 hours, splenic virus titers were determined.26

**Histology**

Organs were fixed with 4% formaldehyde and embedded in paraffin. Sectioning, staining, and analysis were performed as described previously.17

**Patients**

We performed a PubMed search for “Hermansky-Pudlak Syndrome,” “Hermansky-Pudlak syndrome type 2,” “Adaptor protein 3,” and “AP3B1” to identify all published HPS2 patients. We also contacted colleagues involved in the diagnosis of primary immunodeficiencies and HLH to identify additional patients. Material from 4 patients with HPS2 had been referred to the CCI Advanced Diagnostics Unit for functional studies. We contacted the corresponding authors of all relevant publications and all referring physicians to obtain current clinical information. Written informed consent for immunologic evaluation was obtained from the patients or their legal guardians according to the guidelines of the Declaration of Helsinki, as approved by the institutional review board at the University of Freiburg. NK-cell and CTL cytotoxicity and degranulation assays were performed according to local protocols.27

**Statistical analysis**

Tests were performed with the GraphPad InStat software version 3.06. The comparison between data were evaluated with a one-way analysis of variance with post-test. Differences were considered significant at a P < .05.

**Results**

**Pearl mice develop transient HLH after LCMV infection**

To evaluate whether AP-3-deficient mice are at risk of developing HLH, we infected pearl mice with 200 pfu of LCMV-WE.
intravenously. Infection with LCMV has previously been shown to trigger HLH in a number of mouse strains representing models for human defects in lymphocyte cytotoxicity. To model the genetic situation of the single HPS2 patient who developed lethal HLH, we also infected pearl mice carrying an additional heterozygous Rab27a mutation (pearl-ash1/2). Homozygous Rab27a-deficient mice (ashen)19 and PKO15,18 were included as disease controls, and wild-type C57BL/6 mice served as negative controls. Because viral infections per se can cause a number of features of HLH in mice and humans, we applied the full set of HLH diagnostic criteria28 to the LCMV-infected mice with one exception: a decrease in ear temperature, reflecting circulatory centralization, was counted as fever. Thus, mice were considered to undergo HLH, if at least 5 of the 8 human diagnostic criteria were fulfilled. Elevation of serum levels of IFN-γ and elevation of glutamic-pyruvic transaminase (GPT) and lactate dehydrogenase (LDH), which are also characteristic of human HLH, also were assessed and taken as supporting evidence.

After infection with LCMV, wild-type mice showed no changes in body weight and temperature, whereas ashend and PKO mice developed a significant decrease in body weight and temperature until the end of the experiment (d12). Pearl mice and pearl-ash+/− mice also displayed weight loss and a decrease in body temperature starting 6 days after infection but eventually recovered starting at d9 (Figure 1A-B). At the time point of the most obvious disease (d8), wild-type mice showed leukocytosis, whereas pearl and pearl-ash+/− mice had leukopenia that was even more pronounced in ashen and PKO mice (Figure 1C). Pearl, pearl-ash+/−, ashen,
and PKO mice showed anemia and all groups, including wild-type mice, developed thrombocytopenia (Figure 1C). Serum levels of ferritin (Figure 1D), sCD25 (Figure 1E), and IFN-γ (Figure 1F) were elevated in all mutant mice, with the greatest values found in ashen and PKO mice. Splenomegaly was observed in all groups, including wild-type mice, whereas triglycerides were increased in PKO but not in pearl mice (Figure 2A-B), all mutant, but not wild-type mice showed significant elevation of GPT and LDH as well as histopathological evidence of hemophagocytosis (Figure 2C). Finally, splenic NK cells from pearl mice showed impaired degranulation and cytotoxicity in response to NK-sensitive YAC-1 target cells 24 hours after injection of poly(I:C), although the response of individual mice was highly variable (Figure 3).

In summary, pearl mice developed 7 of 8 HLH criteria on d8 after LCMV infection. However, the abnormalities in some parameters

![Figure 2](image-url)

Figure 2. Liver disease and histopathological alterations in pearl mice undergoing LCMV-induced HLH. C57BL/6, pearl, pearl-ash+/−, ashen, and PKO mice were infected with LCMV-WE and 8 days later, serum levels of (A) GPT, LDH, and triglycerides (TG) were determined. (B) Splenomegaly was analyzed by calculating spleen weight in percent of body weight. (C) Representative liver sections stained with anti-F4/80 (original magnification, 10×) obtained at day 8 after infection. Lower left inset: semiquantitative analysis of hemophagocytic macrophages as assessed in 10 high-power visual fields (40×) per mouse. (+) indicates rare; +, few; and ++, frequent. Scale bars represent 100 μm. n.s. indicates not significant (P > .05); *P < .05; **P < .01.

![Figure 3](image-url)

Figure 3. Impaired NK-cell function in pearl mice. C57BL/6, pearl, and PKO mice were injected intraperitoneally with 200 μg of poly (I:C). At 24 hours later, spleen cells were restimulated for 2 hours with YAC-1 target cells or medium as a control in the presence of anti-CD107a antibody (A-B). (A) Representative histograms of NK1.1+CD3− NK cells are shown. Dashed line indicates medium control; solid line indicates restimulation with YAC-1 cells. (B) Degranulation is shown as increase of CD107a expression on NK1.1+CD3− NK cells (ΔCD107a) after restimulation with YAC-1 cells compared with medium control. (C) NK-cell cytotoxicity was determined in a 5-hour 51chromium release assay on YAC-1 target cells. Quantification of NK cells was performed by flow cytometry. Representative data for 3 independent experiments with 3-5 mice/group are shown.
**Pearl CTL have a defect in degranulation and cytotoxicity that contributes to delayed virus control**

Pearl mice show a number of immunological defects, including lack of NKT cells, defects in antigen presentation, and impaired cytotoxicity in vitro. To determine whether reduced cytotoxicity was a critical factor for the impairment of virus control and development of HLH, we analyzed the capacity of pearl CTL to degranulate and to lyse LCMV-infected target cells in vitro and to control LCMV infection in vivo. Eight days after infection with LCMV, pearl CTL showed a moderate but significant reduction in degranulation in response to the immunodominant LCMV gp33 peptide compared with wild-type C57BL/6 mice (Figure 5A-B). This degranulation defect was reflected in a reduced ex vivo cytotoxicity on LCMV-infected target cells (Figure 5D, left), which was more pronounced when CTL activity was analyzed on target cells loaded with a limiting concentration of gp33 peptide (10^−10 M; Figure 5D, right). We then transfused MACS-purified activated CTL from pearl or C57BL/6 control mice into mice that had been infected with 10^6 pfu LCMV 10 hours earlier and determined virus titers in the spleen after additional 18 hours. In this short-term protection assay, virus control depends on perforin-mediated cytotoxicity. While transfusion of activated wild-type CTL could clear the infection in this short-term assay, pearl CTL were not able to fully control the virus (Figure 5C). These data indicated that the CTL cytotoxicity defect contributed to the lack of virus control.

**Pearl CTL are phenotypically and functionally altered on d8 after LCMV infection but regain functionality after virus elimination**

We have recently shown in a mouse model of FHL-4 that HLH in cytotoxicity mutant mice is accompanied by characteristic phenotypic and functional alterations of virus-specific CD8+ T cells. We therefore analyzed the production of intracellular IFN-γ upon gp33 stimulation of spleen cells obtained on days 8 and 12 after LCMV infection. On day 8 after infection, the total frequency of IFN-γ-producing CTL was similar (data not shown), but the relative frequency of IFN-γ^ash CD8^+ T cells was lower in pearl and PKO compared with control mice (Figure 6A). Moreover, the fraction of cells expressing Tfn-a was reduced in the 2 mutant strains compared with control mice (Figure 6B). However, at day 12 the staining pattern for both cytokines returned to normal in pearl mice, whereas PKO CTL remained less responsive to antigen stimulation (Figure 6A-B). A similar pattern was observed when we analyzed the differentiation phenotype of CD8^+ T cells. On day 8, pearl CTL resembled PKO CTL with a reduced fraction of KLRG1^+CD127^− cells (Figure 6C) and of CD44^hiCD62^hi cells (Figure 6D), whereas at day 12 after infection the phenotype of pearl CTL resembled that of wild-type CTL (Figure 6C-D). Thus, the altered phenotype was linked to virus control and was transient in pearl CTL, whereas it persisted in PKO CTL.

**HPS2 patients have a moderate risk of developing HLH**

The findings in the pearl mouse model suggested that because of a less-severe defect in cytotoxicity, the risk of developing HLH is lower and episodes are less severe than in other cytotoxicity mutants. To assess the risk of HLH in human HPS2 patients, we performed a survey of all 12 so-far published patients with HPS2 and 10 additional, previously unreported patients (Table 1). For 5 patients, we had to rely on the information given in the published report; for all other patients, a 2012 update on the clinical evolution of the disease was provided. The mean age at last follow-up was 10.6 years.
(range, 1.25-30 years) and the overall observation covered 234 patient years. There were 5 sibling pairs, 6 patients had compound heterozygous mutations, and 16 had homozygous mutations. All but 1 patient had neutropenia; 12 received granulocyte-stimulating colony factor (G-CSF) therapy. Eighteen patients had recurrent bacterial and viral infections, most of which affecting the respiratory...
Table 1. Patients with HPS2

<table>
<thead>
<tr>
<th>Patient no./ID (reference)*</th>
<th>AP3B1 mutation</th>
<th>Age at last visit, years</th>
<th>Neutropenia</th>
<th>Bleeding</th>
<th>Recurrent infections</th>
<th>Pulmonary fibrosis</th>
<th>NLH</th>
<th>NK or CTL cytotoxicity and/or degranulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>EX10</td>
<td></td>
<td>7</td>
<td>+ (G-CSF)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>c.1063_1064delCAinsTATCAATATC; p.Q355fsX360</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EX16 c. 1789_1790insA; p.I597fsX608</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EX10</td>
<td></td>
<td>4</td>
<td>+ (G-CSF)</td>
<td>+</td>
<td>+</td>
<td>One incomplete episode</td>
<td>Impaired</td>
<td></td>
</tr>
<tr>
<td>c.1063_1064delCAinsTATCAATATC; p.Q355fsX360</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EX16 c. 1789_1790insA; p.I597fsX608</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2 (6)</td>
<td>EX19 c.2078_2165del; p.E693fsX706</td>
<td>6</td>
<td>*+</td>
<td>*+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>P3 (6)</td>
<td>EX2 c.153_156delAGAG p.E52fsX63</td>
<td>7.2</td>
<td>+ (G-CSF)</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>FR5†</td>
<td>EX27 c.3222_3223delTG; p.E1079fs</td>
<td>5‡</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Impaired</td>
</tr>
<tr>
<td>FR1378</td>
<td>EX27 c.3222_3223delTG; p.E1079fs</td>
<td>13‡</td>
<td>+ (G-CSF)</td>
<td>(+)</td>
<td>(+)</td>
<td>+</td>
<td>+</td>
<td>Impaired</td>
</tr>
<tr>
<td>29 (14) FR15 g.del8172bp; p.del491-550</td>
<td>18</td>
<td>+ (G-CSF)</td>
<td>-</td>
<td>+</td>
<td>n.a.</td>
<td>-</td>
<td>n.a.</td>
<td></td>
</tr>
<tr>
<td>30 (14) FR15 g.del8172bp; p.del491-550</td>
<td>21</td>
<td>+ (G-CSF)</td>
<td>-</td>
<td>+</td>
<td>n.a.</td>
<td>-</td>
<td>n.a.</td>
<td></td>
</tr>
<tr>
<td>40 (2)</td>
<td>EX11-12 c.1166_1228del; p.del390-410</td>
<td>22</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>n.a.</td>
<td></td>
</tr>
<tr>
<td>EX16 c.1739T&gt;G; p.L590R</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42 (2)</td>
<td>EX11-12 c.1166_1228del; p.del390-410</td>
<td>27</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>n.a.</td>
</tr>
<tr>
<td>EX16 c.1739T&gt;G; p.L590R</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FR50</td>
<td>Del Exon 16</td>
<td>16‡</td>
<td>+ (G-CSF)</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Impaired</td>
</tr>
<tr>
<td>87 (13) FR5*</td>
<td>Ex15 c.1525C&gt;T; p.R509×</td>
<td>17</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>Ex18 c.1975G&gt;T; p.E659×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FR393 (5) FR393†</td>
<td>EX8 c.904A&gt;T; p.R302×</td>
<td>3‡</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>One lethal episode</td>
<td>Impaired</td>
</tr>
<tr>
<td>EX18 c.2041G&gt;T; p.E681×</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A, P (11) FR393‡</td>
<td>IVS10±5G&gt;A</td>
<td>6</td>
<td>+ (G-CSF)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>n.a.</td>
</tr>
<tr>
<td>C, B</td>
<td>EX1 c.60_delG; p.L20fsX41</td>
<td>1.25‡</td>
<td>+</td>
<td>n.a.</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>C, A</td>
<td>EX1 c.60_delG; p.L20fsX41</td>
<td>2‡</td>
<td>+ (G-CSF)</td>
<td>n.a.</td>
<td>+</td>
<td>+</td>
<td>n.a.</td>
<td>Impaired</td>
</tr>
<tr>
<td>L, M</td>
<td>EX23 c.2770_del; p.L924fsX926</td>
<td>2.5</td>
<td>+ (G-CSF)</td>
<td>(+)</td>
<td>(+)</td>
<td>+</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>W, M</td>
<td>EX23 c.2770_del; p.L924fsX926</td>
<td>11</td>
<td>+ (G-CSF)</td>
<td>(+)</td>
<td>(+)</td>
<td>+</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>M, Z</td>
<td>EX4 c.2057&gt;C; p.L102P</td>
<td>11</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>n.a.</td>
<td></td>
</tr>
<tr>
<td>n.a. (12) FR6*</td>
<td>IVS14+6&gt;T&gt;C</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Impaired</td>
</tr>
<tr>
<td>EX15 c.1619insG; p.A541fsX565</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n.a. (5) inv (1) (q14.1)</td>
<td></td>
<td>2.25</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Impaired</td>
</tr>
</tbody>
</table>

N.a. indicates not available.

*Patient ID in published report.
†Kurnik et al, manuscript submitted 2013.
‡Deceased.

HPS2 is a rare genetic disorder of lysosomal trafficking with clinical manifestations in several organ systems.2,5-7,11-14 As for other subtypes of HPS, affected patients have a diathesis toward bleeding as the result of a platelet storage pool deficiency15 and a risk of lung fibrosis as the result of aberrant repair mechanisms of the lung caused by lysosomal mis trafficking.21 In addition, however, patients with HPS2 have significant immunological problems, manifesting mainly as chronic neutropenia and a susceptibility to infections. This is in part explained by chronic neutropenia reflecting a role for AP-3 in neutrophil development,13,35,36 but HPS2 also involves other immunological abnormalities, such as an impaired development of NKT cells,14 impaired TLR recruitment to phagosomes, and impaired MHC-II

degranulation abnormalities that were similar to that of patients with CHS or GS2 (supplemental Figure 2). Overall, despite a significant degranulation and cytotoxicity defect, human HPS2 appears to confer only a limited risk for developing HLH.

Discussion

HPS2 is a rare genetic disorder of lysosomal trafficking with clinical manifestations in several organ systems.2,5-7,11-14 As for other subtypes of HPS, affected patients have a diathesis toward bleeding as the result of a platelet storage pool deficiency15 and a risk of lung fibrosis as the result of aberrant repair mechanisms of the lung caused by lysosomal mis trafficking.21 In addition, however, patients with HPS2 have significant immunological problems, manifesting mainly as chronic neutropenia and a susceptibility to infections. This is in part explained by chronic neutropenia reflecting a role for AP-3 in neutrophil development,13,35,36 but HPS2 also involves other immunological abnormalities, such as an impaired development of NKT cells,14 impaired TLR recruitment to phagosomes, and impaired MHC-II

tract. Eleven of 20 patients, where this information was available, had clinically relevant episodes of bleeding, and 9 of 18 patients had evidence of lung fibrosis.

Apart from the reported patient with lethal HLH,5 one other patient could be identified who developed 2 transient episodes fulfilling 5 of 8 HLH criteria. Two further patients had spontaneously resolving episodes of fever and cytopenia in association with varicella and CMV infections that did not fulfill the diagnostic criteria but may have represented incomplete manifestations of HLH.6,7 Of the 5 reported deaths in HPS2 patients, 1 was from HLH, 2 from pneumonia in the context of lung fibrosis and 2 after accidents. In 4 patients without any HLH-related symptoms, asymptomatic seroconversion to Epstein-Barr virus, a known strong trigger for HLH, was documented. At least one immunological test addressing NK-cell or CTL cytotoxicity, NK-cell, or CTL degranulation was available from 16 patients. The experimental protocols including local reference values varied from laboratory to laboratory. However, abnormal findings in at least one of these tests were reported in all 16 patients. We also restudied 3 patients with our previously evaluated standardized panel of diagnostic tests.27 In these in vitro tests, they showed
presentation of antigens internalized by phagocytosis. Finally, lytic granule exocytosis depends upon AP-3, leading to deficiencies of NK-cell and CTL mediated cytotoxicity in HPS2. Because of limited patient numbers, little is known about the prognosis of affected patients, which renders treatment decisions difficult. Life-threatening events may encompass episodes of serious bleeding, severe infections, or respiratory failure caused by progressive pulmonary fibrosis. Moreover, the defect in lymphocyte cytotoxicity can predispose patients to HLH. Because HSCT can prevent the risk of HLH in other genetic disorders of cytotoxicity, can correct the platelet defect, and mitigate the increased susceptibility to infection, HSCT is a relevant consideration for HPS2 patients. However, this treatment carries its own risks and may not affect lung fibrosis, so it must be carefully balanced against the natural history of the disease. In this study we combined experimental studies in a mouse model of HPS2 with observations in the largest reported cohort of 22 HPS2 patients to evaluate the extent to which AP-3 deficiency predisposes to HLH. We also examined the effect of other disease manifestations on prognosis.

Pearl mice carry a 793-bp tandem duplication in the Ap3b1 gene altering the reading frame and truncating the protein 130 amino acids from the C-terminus. There are conflicting data concerning residual protein expression in these mice, and we cannot fully exclude the possibility that some functional AP-3 remains. Nevertheless, the mice recapitulate the platelet storage pool deficiency, the pigment dilution, and the lung pathology. They also show impaired NKT cell development and impaired TLR mediated type I IFN responses. In one previous report authors analyzed NK-cell cytotoxicity in pearl mice and found that it was not significantly altered. In our study, we found a mild NK cell and CTL degranulation defect leading to impaired cytotoxicity in pearl mice. This was less pronounced than in PKO mice or in Lyst-mutant souris mice. Nevertheless, there was a clear impact of the defect on CTL-mediated control of LCMV infection. However, in contrast to PKO mice, pearl mice were eventually able to clear the virus from all organs.

The authors of previous studies have shown that lymphocyte cytotoxicity is also significantly impaired in HPS2 patients. Although initial studies who used T-cell lines found a severe defect, subsequent studies demonstrated significant residual activity. Ex vivo NK-cell cytotoxicity was reduced or absent in all reported patients. In the patients collected for our study, different protocols were used to analyze CTL or NK-cell degranulation and/or cytotoxicity, but at least one abnormal test result was reported in all 16 patients analyzed. Of note, CTL cytotoxicity, which is a less sensitive assay, was normal in 3 patients despite abnormal NK-cell degranulation tests. This pattern has been observed previously in patients with variants of CHS associated with a low risk of HLH.

We investigated to what extent the cytotoxicity defect in HPS2 predisposes to HLH. Indeed, as for other cytotoxicity mutants, infection of pearl mice with LCMV-induced HLH as assessed by the 8 criteria that define the human disease. However, in contrast to other strains, the pearl mice recovered spontaneously without any treatment once the virus was controlled. Pearl mice thus represent the first mouse model for transient HLH, represented by a disease course that can also be observed in FHL patients with milder cytotoxicity defects as the result of hypomorphic mutations. The recovery of these mice from HLH after the virus is controlled indicates that the pathogenic uncontrolled immune response inducing HLH is not autonomous but that continuous antigen stimulation is a key factor in the maintenance of the disease. This finding was also reflected by a more detailed analysis of disease-inducing LCMV-specific T cells. At the peak of clinical disease, pearl mice showed phenotypic and functional alterations of CTL that were indistinguishable from those of PKO mice. However, once the virus was controlled, these functional and phenotypic changes disappeared, whereas they were maintained in PKO mice, where virus and disease manifestations persisted.

Our clinical observations indicate that the risk for HPS2 patients to develop HLH is clearly present but much lower than for patients with Griscelli syndrome type 2, CHS, or FHL. Considering our findings in pearl mice, this is likely attributable to the milder defect in cytotoxicity, allowing delayed, but eventually full control of the dysregulated immune response. The fact that pearl mice carrying an additional heterozygous Rab27a mutation showed the same severe course of HLH in our previously reported HPS2 patient was not caused by that additional mutation.

The prognosis of the patients in our cohort was not only determined by HLH alone. Of the 3 patients who died of disease manifestations, 2 died of pneumonia in the context of lung fibrosis. In fact, 9 of 18 patients had evidence of lung fibrosis. This disease manifestation is caused by impaired pulmonary repair mechanism attributable to disturbed vesicle trafficking that may not be corrected by bone marrow transplantation. The neutrophilia was responsive to G-CSF in all patients, significantly reducing the risk of infections. Only a single patient had significant recurrent bleeding episodes. Taken together, this study suggests that pre-emptive HSCT is not indicated in this patient group, as it is in GS2 and some patients with CHS. Nevertheless, HPS2 patients and their treating physicians must be aware of the fact that there is a relevant risk of HLH and must be alert to the early signs of this potentially life-threatening disease manifestation.

Acknowledgments

The authors thank Nadja Goos for excellent technical support.

This study was supported by the Bundesministerium für Bildung und Forschung (BMBF 01 EO 0803), the Thyssen Stiftung, the EU FP7 (CURE-HLH), and in part by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.

Authorship


Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Stephan Ehl, Center of Chronic Immunodeficiency, Breisacher Str. 117, 79106 Freiburg, Germany; e-mail: stephan.ehl@uniklinik-freiburg.de.
References


